Arrowhead Pharmaceuticals (NASDAQ:ARWR) PT Raised to $34.00

Arrowhead Pharmaceuticals (NASDAQ:ARWR – Get Free Report) had its target price hoisted by analysts at Citigroup from $33.00 to $34.00 in a report released on Wednesday, Benzinga reports. The firm presently has a “neutral” rating on the biotechnology company’s stock. Citigroup’s price objective would suggest a potential upside of 8.35% from the stock’s previous close. […]

Related Keywords

United States ,Canada ,America ,Christopher Richard Anzalone ,Fund Management Co ,Royal Bank ,News Ratings For Arrowhead Pharmaceuticals Daily ,Arrowhead Pharmaceuticals Trading Down ,Yousif Capital Management ,Analyst Recommendations For Arrowhead Pharmaceuticals ,Associates Corp ,Securities Exchange Commission ,Citigroup ,Morgan Stanley ,Arrowhead Pharmaceuticals ,Russell Investments Group Ltd ,Insider Activity At Arrowhead Pharmaceuticals ,Arrowhead Pharmaceuticals Inc ,Institutional Trading Of Arrowhead Pharmaceuticals ,Get Free Report ,Pharmaceuticals Trading Down ,Richard Anzalone ,Exchange Commission ,Director Douglas ,Fund Management ,Investments Group ,Capital Management ,Handelsbanken Fonder ,Arrowhead Pharmaceuticals Daily ,Nasdaq Arwr ,Arwr ,Medical ,Boost Price Target ,Citigroup Inc ,